Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) Sees Significant Drop in Short Interest

Laboratorios Farmaceuticos Rovi, S.A. (OTCMKTS:LABFF) was the recipient of a significant drop in short interest in February. As of February 27th, there was short interest totaling 13,289 shares, a drop of 18.0% from the February 12th total of 16,204 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

Laboratorios Farmaceuticos Rovi Stock Performance

Shares of LABFF remained flat at C$65.86 during trading hours on Monday. The business’s 50-day moving average price is C$65.86 and its two-hundred day moving average price is C$65.86. Laboratorios Farmaceuticos Rovi has a 52-week low of C$65.86 and a 52-week high of C$65.86.

Laboratorios Farmaceuticos Rovi Company Profile

Laboratorios Farmacéuticos ROVI SA is a Spanish specialty pharmaceutical company focused on the development, manufacturing and commercialization of injectable therapies. The company has built expertise in low-molecular-weight heparins and long-acting injectable antipsychotics, alongside drug-delivery technologies such as prefilled syringes and autoinjector systems. ROVI’s product portfolio spans both originator and biosimilar medicines, targeting therapeutic areas including psychiatry, oncology and cardiology.

ROVI’s core franchise includes established anticoagulant products based on tinzaparin sodium, as well as innovative depot formulations of risperidone developed using its proprietary in situ microparticle (ISM) technology.